Abstract
The pathogenesis of multiple myeloma (MM), an incurable tumour causing the deregulated proliferation of terminally differentiated B cells, is unknown1. Chromosomal translocations (14q1) affecting band 14q32 and unidentified partner chromosomes are common in this tumour, suggesting that they may cause the activation of novel oncogenes2,3. By cloning the chromosomal breakpoints in an MM cell line, we show that the 14q+ translocation represents a t(6;14)(p25;q32) and that this aberration is recurrent in MM, as it was found in two of eleven MM cell lines. The translocation juxtaposes the immunoglobulin heavy-chain (IgH) locus to MUM1 (multiple myeloma oncogene 1)lIRF4 gene, a member of the interferon regulatory factor (IRF) family known to be active in the control of B-cell proliferation and differentiation. As a result, the MUM1/IRF4 gene is overexpressed—an event that may contribute to tumorigenesis, as MUM1/IRF4 has oncogenic activity in vitro. These findings identify a novel genetic alteration associated with MM, with implications for the pathogenesis and diagnostics of this tumour.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Barlogie, B. et al. Biology and therapy of multiple myeloma in 1996. Sem. Hematol 34, 67–72 (1997).
Dewald, G.W. et al. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma ceH leukemia, or amyloidosis. Blood 66, 380–390 (1985).
Calasanz, M.J. et al. Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer 18, 84–93 (1997).
Taniwaki, M. et al. Nonrandom chromosomal rearrangements of 14q32.3 and 19p13.3 and preferential deletion of 1p in 21 patients with multiple myeloma and plasma cell leukemia. Blood 84, 2283–2290 (1994).
Bergsagel, P.L. et al. Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc. Natl. Acad. Sci. USA 93, 13931–13936 (1996).
Chesi, M. et al. Dysregulation of Cyclin D1 by translocation into an IgH gamma switch region in two multiple myeloma cell lines. Blood 88, 674–681 (1996).
Dalla-Favera, R., Martinotti, S., Gallo, R.C., Erikson, J. & Croce, C.M. Translocation and rearrangements of the c-myc oncogene locus in human undifferentiated B-cell lymphomas. Science 219, 963–967 (1983).
Matsuyama, T. et al. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element ISRE. Nucleic Acids Res. 23, 2127–2136 (1995).
Eisenbeis, C.F., Singh, H. & Storb, U. Pip, a novel IRF family member, is a lymphoid-specific, PU. 1-dependent transcriptional activator. Genes Dev. 9, 1377–1387 (1995).
Yamagata, T. et al. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. Mol. Cell. Biol. 16, 1283–1294 (1996).
Grossman, A. et al. Cloning of human lymphocyte-specific interferon regulatory factor (hLSIRF/hlRF4) and mapping of the gene to 6p23–p25. Genomics 37, 229–233 (1996).
Harada, H. et al. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58, 729–739 (1989).
Bovolenta, C. et al. Molecular interactions between interferon consensus sequence binding protein and members of the interferon regulatory factor family. Proc. Natl. Acad. Sci. USA 91, 5046–5050 (1994).
Veals, S.A. et al. Subunit of an alfa-interferon-responsive transcription factor is related to interferon regulatory factor and Myb families of DNA-binding proteins. Mol. Cell. Biol. 12, 3315–3324 (1992).
Au, W.-C., Moore, P.A., Lowther, W., Juang, Y.-T. & Pitha, P.M. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression of interferon-induced genes. Proc. Natl. Acad. Sci. USA 92, 11657–11661 (1995).
Madisen, L. & Groudine, M. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells. Genes Dev. 8, 2212–2226 (1994).
Iida, S. et al. The t(9;14)(p13;q32) translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88, 4110–4117 (1996).
Neri, A. et al. p53 gene mutations in multiple myeloma are associated with advanced form of malignancy. Blood 81, 128–135 (1993).
Neri, A. et al. Ras oncogene mutation in multiple myeloma. J. Exp. Med. 170, 1715–1725 (1989).
Gaidano, G. & Dalla-Favera, R. Molecular biology of lymphomas. in Principles and Practice of Oncology, 5th Ed. (eds DeVita, V.T., Hellman, S. & Rosenberg, S.A.) 2131–2144. (J.B. Lippincott, Philadelphia, (1997).
Harada, H. et al. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 259, 971–974 (1993).
Tanaka, N. et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77, 829–839 (1994).
Tamura, T. et al. An IRF-1-dependent pathway of DMA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature 376, 596–599 (1995).
Holtschke, T. et al. Immunodeficiency and chronic myelogeneous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87, 307–317 (1996).
Mittrücker, H.-W. et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science 275, 540–543 (1997).
Klein, B. et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 73, 517–526 (1989).
Eton, O., Scheinberg, D.A. & Houghton, A.N. Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia 3, 729–735 (1989).
Jernberg, H., Zech, L. & Nilsson, K. Cytogenetic studies on human myeloma cell lines. Int. J. Cancer 40, 811–817 (1987).
Zhang, X.-G. et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 83, 3654–3663 (1994).
Gu, W., Cechova, K., Tassi, V. & Dalla-Favera, R. Opposite regulation of gene transcription and cell proliferation by c-Myc and Max. Proc. Natl. Acad. Sci. USA 90, 2935–2939 (1993).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Iida, S., Rao, P., Butler, M. et al. Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet 17, 226–230 (1997). https://doi.org/10.1038/ng1097-226
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ng1097-226
This article is cited by
-
Large B-cell lymphoma with IRF4 rearrangement: a multi-centric study with focus on potential misleading phenotypes
Virchows Archiv (2024)
-
Clinical Relevance of Interferon Regulatory Family-4 (IRF4) Expression in Newly Diagnosed Patients with Multiple Myeloma
Indian Journal of Hematology and Blood Transfusion (2023)
-
IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma
Nature Communications (2022)
-
The dynamic functions of IRF4 in B cell malignancies
Clinical and Experimental Medicine (2022)
-
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia
Frontiers of Medicine (2022)